Background: COVID-19-associated coagulopathy is a life-threatening complication of SARS-CoV-2 infection with increased mortality and morbidity rate, especially in patients with severe or underlying chronic disease. The prevalence of chronic viral hepatitis in Egypt is much higher than other countries. Chronic viral hepatitis in association with covid disease can increase the risk of severe complications. Since Coagulopathy in patients with liver disease results from impairment in the clotting and fibrinolytic systems, as well as reduced number and function of platelets, understanding the effect of viral hepatitis on the coagulation state of covid 19 patients is of scientific and clinical importance if novel strategies are to be developed that can help in the management of the patients